Comparative Pharmacology
Head-to-head clinical analysis: CYLTEZO versus ERELZI.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CYLTEZO versus ERELZI.
CYLTEZO vs ERELZI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Adalimumab is a recombinant human monoclonal antibody that binds to tumor necrosis factor-alpha (TNFα) and blocks its interaction with p55 and p75 cell surface TNF receptors. It also modulates biological responses induced or regulated by TNFα, including adhesion molecules, chemotaxis, and matrix metalloproteinases.
Erelzi (etanercept-szzs) is a tumor necrosis factor (TNF) blocker. It is a dimeric fusion protein consisting of the extracellular ligand-binding portion of the human 75 kilodalton (p75) TNF receptor linked to the Fc portion of human IgG1. Erelzi binds specifically to TNF-alpha and blocks its interaction with cell surface TNF receptors, thereby reducing TNF-mediated inflammatory responses.
Adalimumab 40 mg subcutaneously every other week, with or without methotrexate, for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and plaque psoriasis. For ulcerative colitis and hidradenitis suppurativa, day 1: 160 mg (four 40 mg injections in one day or two 40 mg injections per day for two days), day 15: 80 mg, then 40 mg every other week starting day 29. For uveitis, 40 mg every other week.
For plaque psoriasis: 100 mg subcutaneous injection once weekly, after initial loading dose of 200 mg at weeks 0, 1, 2, 3, and 4. For psoriatic arthritis: 100 mg subcutaneous injection once weekly.
None Documented
None Documented
Approximately 14 days (range 10–20 days) following subcutaneous administration; supports every-other-week dosing.
Terminal elimination half-life: 13–16 days (mean 14.6 days) in adults with moderate-to-severe plaque psoriasis; clinical context: supports every-2-week subcutaneous dosing regimen.
Primarily eliminated via intracellular catabolism; no significant renal or biliary elimination of intact adalimumab.
Renal: negligible (not significantly excreted unchanged); Biliary/Fecal: primary elimination pathway via proteolytic catabolism to amino acids; approximately 95% of dose recovered as small peptides/amino acids in feces.
Category C
Category C
TNF-alpha Inhibitor
TNF-alpha Inhibitor